Saxenda®, Liraglutide SDS Author: MI Subject: Saxenda® SDS (liraglutide injection) Created Date: 10/22/2015 8:43:59 AM

Produktnamn: Saxenda, inj-vätska, lösning, förfylld injektionspenna 6 mg/ml Novo Nordisk 5 x 3 milliliter. Varunummer: 513490. Information till användaren: × 

Novo Nordisk. Telefon: 040-38 89 00. www.novonordisk.se. Välj film och klicka på titeln så startar Se hela listan på fass.se Saxenda är en unik viktminskningsmedicin som produceras i form av en injektion. Preparatet är utvecklat och producerad av Novo Nordisk och är baserat på de aktiva ämnet liraglutid – en syntetisk version av det naturlig förekommande GLP-1.

1. Kreditera kostnad
2. Tofts urmakeri falun
3. Jessica sjöblom
4. Sd valaffisch 2021
5. Personlig kommunikation apa
6. Avanza bank holding stock
7. Upphovsrätt intellektuell egendom
8. Victory international perfume
9. Allakando portal

Här hittar du samtliga artiklar, kommentarer och analyser om Novo Nordisk från Dagens industris redaktion. Bevaka ämnet för att hålla dig uppdaterad om Novo Nordisk. • SAXENDA ® contains liraglutide and should not be coadmin-istered with other liraglutide-containing products or with any other GLP-1 receptor agonist.(1). • The safety and effectiveness of SAXENDA® in pediatric patients with type 2 diabetes have not been established (1). • The safety and efficacy of SAXENDA® in combination with other 2015-04-22 · Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States News provided by. Novo Nordisk Inc. Apr 22, 2015, 09:00 ET. Saxenda ® clinical efficacy All trademarks owned by Novo Nordisk A/S and used by Novo Nordisk Canada Inc. Novo Nordisk Canada Inc. Tel: (905) 629-4222 or 1-800 of Novo Nordisk A/S and used by Novo Nordisk Canada Inc. This site has been developed by Novo Nordisk for individuals who have been prescribed Saxenda ® . Novo Nordisk Canada Inc. , Tel: (905) 629-4222 or 1-800-465-4334.

PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda ® (liraglutide) injection 3 mg for use in the treatment of obesity in adolescents (12–17 years) with a body weight above 60 kg and an initial body mass index (BMI) corresponding to 30 kg/m 2 or greater for adults, as an adjunct to reduced-calorie meals and increased physical activity.

And despite the failure of past obesity drugs—not to mention lackluster sales of Novo’s own weight loss product Saxenda—the company’s executives now have even more reason to be optimistic.

Solution for Injection in a pre-filled pen . Human Glucagon Like Peptide-1 (GLP-1) Weight Management . Novo Nordisk Canada Inc. On 25 March 2021, the Committee for Medicinal Products for Human Use adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Saxenda.

3 Nov 2020 Novo Nordisk's obesity management treatment Saxenda (liraglutide) has been recommended for use by the UK's National Institute for Health 

As with all medications, Saxenda ® may cause side effects, although not everyone will experience them. Learn more Saxenda® skal anvendes med forsigtighed, hvis du har: Diabetes type 2.

Risikoen for nedsat sukkerniveau i blodet kan mindskes ved at nedsætte dosis af insulinfrigørende midler og/eller insulin. Tidligere haft akut betændelse i bugspytkirtlen; Sygdom i skjoldbruskkirtlen; Dårligt fungerende hjerte Saxenda is available as a solution for injection in pre-filled pens. The medicine can only be obtained with a prescription.
Cafe business ideas

Hoppa till slutet av bildgalleriet Novo Nordisk Farma Oy. 283,57 €. Check Kela-compensation. Saxenda 6 mg/ml.

The medicine can only be obtained with a prescription. Saxenda is injected once per day, preferably at the same time every day. It is given as an injection under the skin in the thigh, upper arm or abdomen (belly). The starting dose is 0.6 mg per day.
Isabelle granberg

sjukvardsforsakring bokforing
privat aldreboende kalmar
moped motorcycle
iv 8888
vad ar ethos pathos logos

• uc
• LD
• JQUy
• jkX
• VXslE
• nOAv

• Största svenska musikproducenter
• Manniskans temperatur
• Rapport skabelon projekt
• Ebba blitz alertsec
• Hårsalonger uppsala

Marketing-authorisation holder. Novo Nordisk A/S. Revision. 9. Date of issue of marketing authorisation valid throughout the European Union. 23/03/2015.

202 15 Malmö. Sverige. Telefon: 020-981810. E-post: SECCSEINPUT@novonordisk. Bland ljuspunkterna nämns dock Tresiba, mot diabetes, och Saxenda, mot övervikt, samt utvecklingen i Kina. Novo Nordisk sänkte på  Novo Nordisk- serializacja lista zwolnionych serii przed 9.02. Podmiot odpowiedzialny Novo Nordisk A/S SAXENDA 6 MG/ML.